SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chemotherapy in non–small cell lung cancer—a meta-analysis using updated data on individual patients from 52 randomized clinical trials. non–small cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
  • 2
    Grilli R, Oxyman A, Julian J. Chemotherapy for advanced non–small cell lung cancer: how much benefit is enough? J Clin Oncol. 1993;11:1866-1872.
  • 3
    Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non–small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
  • 4
    Fossella F, DeVore R, Kerr R, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non–small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354-2362.
  • 5
    Hanna N, Shepherd F, Fossella F, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-1597.
  • 6
    Adjei A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004;10:S4276-S4280.
  • 7
    Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
  • 8
    Herbst R, Bunn P Jr. Targeting the epidermal growth factor receptor in non–small cell lung cancer. Clin Cancer Res. 2003;9:5813-5824.
  • 9
    Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10:461-466.
  • 10
    Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
  • 11
    Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-145.
  • 12
    Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
  • 13
    Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;363:2380-2388.
  • 14
    Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol. 2010;11:121-128.
  • 15
    Zhou C, Wu YL, Chen G, et al. Erlotinib vs chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study. Lancet Oncol. 2011;12:735-742.
  • 16
    Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:4068-4070.
  • 17
    Zhu CQ, Santos GC, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol. 2008;26:4268-4275.
  • 18
    Schneider CP, Heigener D, Schott von Romer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non–small cell lung cancer. An analysis of patients from German centers in the TRUST study. J Thorac Oncol. 2008;3:1446-1453.
  • 19
    Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non–small cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962-972.
  • 20
    Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non–small cell lung cancer: a meta-analyses of 22 studies. Lung Cancer. 2010;69:272-278.
  • 21
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
  • 22
    National Cancer Institute. Common Toxicity Criteria for Adverse Events. Bethesda, MD: National Cancer Institute; 2012. Available at: http://www.eortc.be/services/doc/ctc/ctcv20_4-30-992.pdf. [Access April 18, 2013].
  • 23
    Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008;99:923-929.
  • 24
    Ciuleanu T, Stelmakh L, Cicenas S, et al. Erlotinib vs docetaxel or pemetrexed as second-line therapy in patients with advanced NSCLC and poor prognosis: efficacy and safety results from the phase III TITAN study. Lancet Oncol. 2012;3:300-308.
  • 25
    Kim ES, Hirsh V, Mok T, et al. Gefitinib vs docetaxel in previously treated non–small cell lung cancer (INTEREST): a randomized phase III trial. Lancet. 2008;372:1809-1818.
  • 26
    Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008;26:4244-4252.
  • 27
    Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non–small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010;16:1307-1314.
  • 28
    Douillard J-Y, Shepherd F, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2009;28:744-752.
  • 29
    Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-967.
  • 30
    Garassino MC, Martelli O, Bettini A, et al. TAILOR: a phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR [abstract]. J Clin Oncol. 2012;30(18 suppl). Abstract LBA7501.
  • 31
    Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non–small cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol. 2012;3:239-246.
  • 32
    Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non–small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011;4:774-780.